MIF and melanoma: These data are consistent with our lab’s finding that MIF-stromal deficiency and the small molecule MIF enzymatic inhibitor, 4-IPP (99), reduce melanoma primary and metastatic tumor growth in a manner that coincides with reduced M-MDSC and PMN-MDSC (aka, G-MDSCs)-dependent immune suppression (90).